From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia

Gurnari, Carmelo; Voso, Maria Teresa; Maciejewski, Jaroslaw P.; Visconte, Valeria

doi:10.3390/cancers12020357

Cited by 13 publications

(7 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, lymphomas arise from lymphocytes at different stages of development, and their subtype characteristics, B-cell and T-cell tumors, reflect the cells of origin ( 89 ). Leukemia, on the other hand, is a heterogeneous group of diseases characterized by clonal expansion, abnormal proliferation of undifferentiated myeloid or lymphoid progenitors, and variable responses to treatment ( 90 ). Moreover, MM is a malignant plasma cell (PC) disorder originating from PCs formed by B-lymphocyte development in the bone marrow ( 91 ).…”

Section: Application Of Ferroptosis In Hematologic Malignanciesmentioning

confidence: 99%

Molecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies

2021

View full text Add to dashboard Cite

Cell death is essential for the normal metabolism of human organisms. Ferroptosis is a unique regulated cell death (RCD) mode characterized by excess accumulation of iron-dependent lipid peroxide and reactive oxygen species (ROS) compared with other well-known programmed cell death modes. It has been currently recognized that ferroptosis plays a rather important role in the occurrence, development, and treatment of traumatic brain injury, stroke, acute kidney injury, liver damage, ischemia–reperfusion injury, tumor, etc. Of note, ferroptosis may be explained by the expression of various molecules and signaling components, among which iron, lipid, and amino acid metabolism are the key regulatory mechanisms of ferroptosis. Meanwhile, tumor cells of hematological malignancies, such as leukemia, lymphoma, and multiple myeloma (MM), are identified to be sensitive to ferroptosis. Targeting potential regulatory factors in the ferroptosis pathway may promote or inhibit the disease progression of these malignancies. In this review, a systematic summary was conducted on the key molecular mechanisms of ferroptosis and the current potential relationships of ferroptosis with leukemia, lymphoma, and MM. It is expected to provide novel potential therapeutic approaches and targets for hematological malignancies.

show abstract

Section: Application Of Ferroptosis In Hematologic Malignanciesmentioning

confidence: 99%

Molecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies

2021

View full text Add to dashboard Cite

show abstract

“…Unlike Leukostrat, which cannot reliably quantitate VAF, dPCR–HSAFM was quantitative across the entire admixture range of 5–100%. Since VAF is an important indicator of patient prognosis, ,,,− accurate and routine quantitation of VAF could mean earlier capture of minimal residual disease or relapse, enabling timely, targeted therapy for FLT3 -ITD patients. , Thus, a platform such as dPCR–HSAFM that can rapidly and cost-effectively report FLT3 -ITD length and VAF across a wide range of lengths is potentially advantageous.…”

Section: Resultsmentioning

confidence: 99%

Digital Polymerase Chain Reaction Paired with High-Speed Atomic Force Microscopy for Quantitation and Length Analysis of DNA Length Polymorphisms

et al. 2020

View full text Add to dashboard Cite

DNA length polymorphisms are found in many serious diseases, and assessment of their length and abundance is often critical for accurate diagnosis. However, measuring their length and frequency in a mostly wild-type background, as occurs in many situations, remains challenging due to their variable and repetitive nature. To overcome these hurdles, we combined two powerful techniques, digital polymerase chain reaction (dPCR) and high-speed atomic force microscopy (HSAFM), to create a simple, rapid, and flexible method for quantifying both the size and proportion of DNA length polymorphisms. In our approach, individual amplicons from each dPCR partition are imaged and sized directly. We focused on internal tandem duplications (ITDs) located within the FLT3 gene, which are associated with acute myeloid leukemia and often indicative of a poor prognosis. In an analysis of over 1.5 million HSAFM-imaged amplicons from cell line and clinical samples containing FLT3-ITDs, dPCR–HSAFM returned the expected variant length and variant allele frequency, down to 5% variant samples. As a high-throughput method with single-molecule resolution, dPCR–HSAFM thus represents an advance in HSAFM analysis and a powerful tool for the diagnosis of length polymorphisms.

show abstract

“…is orally available, investigational drug exhibiting potential antitumor activity [49,50]. Pracinostat is a small molecule next generation histone diacetylases (HDAC) inhibitor indicated acute myeloid leukemia [51].…”

Section: Dovitinib (6)mentioning

confidence: 99%

Advances of Benzimidazole Derivatives as Anticancer Agents: Bench to Bedside

Haider¹,

Yar²

2022

Biochemistry

View full text Add to dashboard Cite

Benzimidazole is one of the privileged nitrogen-containing scaffolds known for its versatile diversified role in insecticides, pesticides, dyes, pigments and pharmaceuticals. Due to its electron-rich environment, structural features and binding potency of various therapeutic targets, benzimidazole derivatives exhibit a broad spectrum of biological activity that majorly includes antimicrobial, antifungal, analgesics, anti-diabetic and anticancer agents. Several benzimidazole scaffolds bearing drugs are clinically approved; they are used for various indications. For example, Bilastine, Lerisetron, Maribavir and Nocodazole are the most widely used benzimidazole-based marketed drugs available as an antihistamine, antiviral and antimitotic agent, respectively. Another example is the recently approved anticancer drug Binimetinib and Selumetinib, which are indicated for BRAF mutated melanoma and plexiform neurofibromas. Not only this, many benzimidazole-based anticancer drugs are in late phases of clinical development. Due to the vast therapeutic potential of benzimidazole scaffold in cancer research, medicinal chemists have gained a lot of attraction to explore it more and develop novel, highly effective and target-specific benzimidazole-based potential anticancer drugs.

show abstract

From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia

Cited by 13 publications

References 105 publications

Molecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies

Molecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies

Digital Polymerase Chain Reaction Paired with High-Speed Atomic Force Microscopy for Quantitation and Length Analysis of DNA Length Polymorphisms

Advances of Benzimidazole Derivatives as Anticancer Agents: Bench to Bedside

Contact Info

Product

Resources

About